贝达喹啉和德拉马尼在治疗儿童耐药结核病中的研究进展

doi:10.12372/jcp.2023.22e1064

Abstract

Abstract:

Tuberculosis (TB) is one of the major global public health concerns, and drug-resistant TB is one of the major obstacles to achieve the goal of ending TB due to the long treatment period, complicated regimens, multiple adverse effects and poor efficacy. In recent years, bedaquiline and delamanid have gradually become promising new drugs, but there is lack of researches on the application of these drugs in children with drug-resistant tuberculosis in China. This article reviews the efficacy and safety of bedaquiline and delamanid in drug-resistant tuberculosis and the progress of their use in children, in order to help construct new and effective regimens for the treatment of drug-resistant tuberculosis in children.

Key words: tuberculosis, drug-resistant tuberculosis, bedaquiline, delamanid, child

WANG Xiyu, XU Hongmei. Advances in the study of bedaquiline and delamanid in the treatment of drug-resistant tuberculosis in children[J].Journal of Clinical Pediatrics, 2023, 41(5): 387-393.

References 52

[1]	World Health Organization. Global tuberculosis raport 2021 [EB/OL]. [2022-08-08]. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021.
[2]	Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study[J]. Lancet Infect Dis, 2016, 16(10): 1193-1201. doi: S1473-3099(16)30132-3 pmid: 27342768
[3]	Jenkins HE, Tolman AW, Yuen CM, et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates[J]. Lancet, 2014, 383(9928): 1572-1579. doi: 10.1016/S0140-6736(14)60195-1 pmid: 24671080
[4]	Jenkins HE, Yuen CM. The burden of multidrug-resistant tuberculosis in children[J]. Int J Tuberc Lung Dis, 2018, 22(5): 3-6. doi: 10.5588/ijtld.17.0357 pmid: 29665947
[5]	Tadolini M, Garcia-Prats AJ, D'ambrosio L, et al. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges[J]. Eur Respir J, 2016, 48(3): 938-943. doi: 10.1183/13993003.00705-2016 pmid: 27338197
[6]	Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline[J]. N Engl J Med, 2014, 371(8): 723-732. doi: 10.1056/NEJMoa1313865
[7]	Field SK. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?[J]. Ther Adv Chronic Dis, 2015, 6(4): 170-184. doi: 10.1177/2040622315582325 pmid: 26137207
[8]	Dhillon J, Andries K, Phillips PP, et al. Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells[J]. Tuberculosis (Edinb), 2010, 90(5): 301-305. doi: 10.1016/j.tube.2010.07.004
[9]	刘盛盛, 王莲芝, 唐神结. 耐多药和利福平耐药结核病化学治疗研究进展[J]. 中华结核和呼吸杂志, 2020, 43(4): 371-375.
[10]	Pym AS, Diacon AH, Tang SJ, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis[J]. Eur Respir J, 2016, 47(2): 564-574. doi: 10.1183/13993003.00724-2015 pmid: 26647431
[11]	Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study[J]. Eur Respir J, 2017, 49(5):1700387. doi: 10.1183/13993003.00387-2017
[12]	Koirala S, Borisov S, Danila E, et al. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: results from a large global cohort[J]. Pulmonology, 2021, 27(5): 403-412. doi: 10.1016/j.pulmoe.2021.02.006
[13]	Cox E, Laessig K. FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis[J]. N Engl J Med, 2014, 371(8): 689-691. doi: 10.1056/NEJMp1314385
[14]	Schnippel K, Ndjeka N, Maartens G, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study[J]. Lancet Respir Med, 2018, 6(9): 699-706. doi: 10.1016/S2213-2600(18)30235-2 pmid: 30001994
[15]	Achar J, Hewison C, Cavalheiro AP, et al. Off-label use of bedaquiline in children and adolescents with multidrug-resistant tuberculosis[J]. Emerg Infect Dis, 2017, 23(10): 1711-1713. doi: 10.3201/eid2310.170303
[16]	Harausz EP, Garcia-Prats AJ, Seddon JA, et al. New and repurposed drugs for pediatric multidrug-resistant tuberculosis. Practice-based recommendations[J]. Am J Respir Crit Care Med, 2017, 195(10): 1300-1310. doi: 10.1164/rccm.201606-1227CI
[17]	Gubkina MF, Khokhlova JY, Yukhimenko NV, et al. Prolonged use of bedaquiline in the treatment for MDR-TB in a child[J]. IDCases, 2021, 26: e01311. doi: 10.1016/j.idcr.2021.e01311
[18]	Hughes JA, Solans BP, Draper HR, et al. Pharmacokinetics and safety of bedaquiline in HIV-positive and negative older children and adolescents with rifampicin-resistant tuberculosis[J]. Clin Infect Dis, 2022, 75(10):1772-1780. doi: 10.1093/cid/ciac252 pmid: 35377434
[19]	Solodovnikova V, Kumar AMV, Hurevich H, et al. Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: a nationwide study from Belarus, 2015-19[J]. Monaldi Arch Chest Dis, 2021, 91(1). doi: 10.4081/monaldi.2021.1646. doi: 10.4081/monaldi.2021.1646
[20]	Das M, Mamnoon F, Mansoor H, et al. New TB drugs for the treatment of children and adolescents with rifampicin-resistant TB in Mumbai, India[J]. Int J Tuberc Lung Dis, 2020, 24(12): 1265-1271. doi: 10.5588/ijtld.20.0165 pmid: 33317670
[21]	Wu HY, Tian Y, Wang XD, et al. Twenty-four-week interim outcomes of bedaquiline-containing regimens in treatment of adolescents with rifampicin-resistant tuberculosis: a retrospective cohort study in China[J]. J Paediatr Child Health, 2022, 58(1): 116-121. doi: 10.1111/jpc.v58.1
[22]	Moodliar R, Aksenova V, Frias MVG, et al. Bedaquiline for multidrug-resistant TB in paediatric patients[J]. Int J Tuberc Lung Dis, 2021, 25(9): 716-724. doi: 10.5588/ijtld.21.0022 pmid: 34802493
[23]	Evaluating the pharmacokinetics, safety, and tolerability of bedaquiline in HIV-infected and HIV-uninfected infants, children, and adolescents with multidrug-resistant tuberculosis[EB/OL]. [2022-08-08]. https://clinicaltrials.gov/ct2/show/NCT02906007.
[24]	Pontali E, Sotgiu G, Tiberi S, et al. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence[J]. Eur Respir J, 2017, 50(5):1701462. doi: 10.1183/13993003.01462-2017
[25]	Brust JCM, Gandhi NR, Wasserman S, et al. Effectiveness and Cardiac safety of bedaquiline-based therapy for drug-resistant tuberculosis: a prospective cohort study[J]. Clin Infect Dis, 2021, 73(11): 2083-2092. doi: 10.1093/cid/ciab335 pmid: 33882121
[26]	Marais BJ. Newer drugs for tuberculosis prevention and treatment in children[J]. Indian J Pediatr, 2019, 86(8): 725-731. doi: 10.1007/s12098-018-02854-8 pmid: 30707347
[27]	抗结核新药贝达喹啉临床应用专家共识(2020年更新版)[J]. 中华结核和呼吸杂志, 2021, 44(2): 81-87.
[28]	World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim guidance[M/OL]. [2022-08-08]. Geneva: World Health Organization, 2013. https://apps.who.int/iris/bitstream/handle/10665/84879/9789241505482_eng.pdf.
[29]	Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis[J]. MMWR Recomm Rep, 2013, 62(Rr-09): 1-12. pmid: 24157696
[30]	Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB)[EB/OL]. [2022-08-08]. https://www.who.int/publications/i/item/WHO-CDS-TB-2018.18.
[31]	World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment 2019[M/OL]. [2022-08-08]. Geneva, World Health Organization, 2019. https://www.who.int/publications/i/item/9789241550529.
[32]	Liu Y, Matsumoto M, Ishida H, et al. Delamanid: from discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)[J]. Tuberculosis (Edinb), 2018, 111: 20-30. doi: 10.1016/j.tube.2018.04.008
[33]	Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis[J]. N Engl J Med, 2012, 366(23): 2151-2160. doi: 10.1056/NEJMoa1112433
[34]	Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis[J]. Eur Respir J, 2013, 41(6): 1393-400. doi: 10.1183/09031936.00125812 pmid: 23018916
[35]	Blair HA, Scott LJ. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis[J]. Drugs, 2015, 75(1): 91-100. doi: 10.1007/s40265-014-0331-4 pmid: 25404020
[36]	Gupta R, Geiter LJ, Wells CD, et al. Delamanid for extensively drug-resistant tuberculosis[J]. N Engl J Med, 2015, 373(3): 291-292. doi: 10.1056/NEJMc1415332
[37]	Von Groote-Bidlingmaier F, Patientia R, Sanchez E, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial[J]. Lancet Respir Med, 2019, 7(3): 249-259. doi: 10.1016/S2213-2600(18)30426-0 pmid: 30630778
[38]	Esposito S, D'ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use[J]. Eur Respir J, 2014, 44(3): 811-815. doi: 10.1183/09031936.00060414 pmid: 24833763
[39]	Esposito S, Bosis S, Tadolini M, et al. Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis: a case report and review of the literature[J]. Medicine (Baltimore), 2016, 95(46): e5347. doi: 10.1097/MD.0000000000005347
[40]	Ghosh S, Breitscheidel L, Lazarevic N, et al. Com-passionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update[J]. Eur Respir J, 2021, 57(5): 2002483. doi: 10.1183/13993003.02483-2020
[41]	European Medicines Agency, Amsterdam, The Netherlands. Deltyba European public assessment report (EPAR)[EB/OL]. [2022-08-08]. https://www.ema.europa.eu/en/documents/variation-report/deltyba-h-c-2552-ii-0040-epar-assessment-report-variation_en.pdf.
[42]	European Medicines Agency, Amsterdam, The Netherlands. Deltyba European public assessment report (EPAR)[EB/OL]. [2022-08-08]. https://www.ema.europa.eu/en/documents/variation-report/deltyba-h-c-002552-x-0046-g-epar-assessment-report-variation_en.pdf.
[43]	Garcia-Prats AJ, Frias M, Van Der Laan L, et al. Delamanid added to an optimized background regimen in children with multidrug-resistant tuberculosis: results of a phase I/II clinical trial[J]. Antimicrob Agents Chemother, 2022, 66(5): e0214421. doi: 10.1128/aac.02144-21
[44]	Pharmacokinetic and safety trial to determine the appropriate dose for pediatric patients with multidrug resistant tuberculosis[EB/OL]. [2022-08-08]. https://clinicaltrials.gov/ct2/show/NCT01856634.
[45]	A 6-month safetyefficacy, and pharmacokinetic (PK) trial of delamanid in pediatric participants with multidrug resistant tuberculosis (MDR-TB)[EB/OL]. [2022-08-08]. https://clinicaltrials.gov/ct2/show/NCT01859923.
[46]	Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB[EB/OL]. [2022-08-08]. https://clinicaltrials.gov/ct2/show/NCT03141060.
[47]	Ryan N, Lo J. Delamanid: first global approval[J]. Drugs, 2014, 74(9): 1041-1045. doi: 10.1007/s40265-014-0241-5 pmid: 24923253
[48]	Lewis JM, Sloan DJ. The role of delamanid in the treatment of drug-resistant tuberculosis[J]. Ther Clin Risk Manag, 2015, 11: 779-791.
[49]	Sasaki T, Svensson EM, Wang X, et al. Population Pharmacokinetic and concentration-QTc analysis of delamanid in pediatric participants with multidrug-resistant tuberculosis[J]. Antimicrob Agents Chemother, 2022, 66(2): e0160821. doi: 10.1128/AAC.01608-21
[50]	World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: interim policy guidance[M/OL]. [2022-08-08]. Geneva: World Health Organization, 2016. https://www.who.int/publications/i/item/9789241549899.
[51]	World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment[M/OL]. [2022-08-08]. Geneva: World Health Organization, 2016. https://www.who.int/publications/i/item/9789241550529
[52]	World Health Organization. WHO consolidated guidelines on tuberculosis: Module 5: Management of tuberculosis in children and adolescents[M/OL]. [2022-08-08]. Geneva: World Health Organization, 2016. https://www.who.int/publications/i/item/9789240046764.

Advances in the study of bedaquiline and delamanid in the treatment of drug-resistant tuberculosis in children

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 52

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LIN Jinfeng, CHEN Yi, DENG Yan, FENG Ai, HUANG Juan, CHEN Lizhu, XIE Jingqi, NIE Xiaojing. A comparative study on the detection of anti-Nephrin antibodies in children's nephrotic syndrome by chemiluminescence method and cell-based assay [J]. Journal of Clinical Pediatrics, 2026, 44(8): 682-689.
[2]	ZHENG Fangyuan, WANG Miao, DING Mingming, LU Aidong, JIA Yueping, ZENG Huimin, ZHANG Leping. Next-generation sequencing identified gene variants and their prognostic impact in pediatric Philadelphia chromosome positive acute lymphoblastic leukemia [J]. Journal of Clinical Pediatrics, 2026, 44(8): 690-697.
[3]	ZHANG Xiao, FANG Hongjun, KUANG Xiaojun, WANG Lijuan, WU Zhao, JIANG Sha, LI Pei, WU Liwen. Analysis of the clinical and electrophysiological characteristics of atonic seizures in children [J]. Journal of Clinical Pediatrics, 2026, 44(8): 698-704.
[4]	WANG Mengqian, YANG Hui. Case series analysis of 13 intestinal Behcet’s syndrome in children [J]. Journal of Clinical Pediatrics, 2026, 44(8): 705-711.
[5]	WU Xirong, GAO Qi, GUO Siyuan, YIN Qingqin, QIN Qiang, YIN Ju, JIAO Anxia, CHEN Chenghao, WU Di, WANG Bei, DUAN Xiaomin, PENG Yun, XU Baoping, GAO Liwei. Clinical characteristics and prognosis of pulmonary mucormycosis in children with diabetes mellitus [J]. Journal of Clinical Pediatrics, 2026, 44(8): 712-720.
[6]	HAN Yanan, GE Lanlan, CUI Jieyuan. A case report of branchio-oto-renal syndrome caused by EYA1 gene variant with a 6-year follow-up [J]. Journal of Clinical Pediatrics, 2026, 44(8): 721-726.
[7]	SHI Jiayi, GAO Chunlin, JIA Lili, LU Yunyun, SUN Tao, ZHU Xiaodong, XIA Zhengkun, ZHANG Pei. Phenotypic characteristics and prognostic analysis of a pedigree with childhood isolated nephrotic syndrome caused by compound heterozygous mutations in the COQ2 gene [J]. Journal of Clinical Pediatrics, 2026, 44(8): 727-732.
[8]	Rachel Rosen, Osvaldo Borrelli, Christophe Faure, Katja Karrento, Usha Krishnan, Samuel Nurko, Nathalie Rommel, Alan Silverman, Michiel van Wijk, Marc Benninga (Author), Chinese Medical Association Parenteral and Enteral Nutrition Branch Pediatrics Group, The Subspecialty Group of Gastroenterology, The Society of Pediatric, Chinese Medical Association, Gastroenterology Group, Pediatrician Branch, Chinese Medical Doctor Association (Translator). Core interpretation and explanation of Rome Ⅴ diagnostic criteria: upper gastrointestinal disorders of gut-brain interaction in children and adolescents [J]. Journal of Clinical Pediatrics, 2026, 44(7): 595-608.
[9]	Carlo Di Lorenzo, Miguel Saps, Bruno P. Chumpitazi, Shaman Rajindrajith, Annamaria Staiano, Nikhil Thapar, Miranda van Tilburg, Carlos Velasco-Benítez, Arine Vlieger (Author), Chinese Medical Association Parenteral and Enteral Nutrition Branch Pediatrics Group, The Subspecialty Group of Gastroenterology, The Society of Pediatric, Chinese Medical Association, Gastroenterology Group, Pediatrician Branch, Chinese Medical Doctor Association (Translator). Core interpretation and explanation of Rome Ⅴ diagnostic criteria: lower and biliary disorders of gut-brain interaction in children and adolescents [J]. Journal of Clinical Pediatrics, 2026, 44(7): 609-621.
[10]	LI Xufeng, TANG Haoxun, LI Xingjun, ZHANG Lize, GAO Chenqing, ZHAO Shunying, LIU Jianhua. Clinical characteristics, chest CT imaging phenotypes, and their correlation with prognosis in 76 children with Chlamydia pneumoniae pneumonia [J]. Journal of Clinical Pediatrics, 2026, 44(7): 622-627.
[11]	WANG Zhen, SHAO Jingbo, ZHANG Na, XIA Min, ZHU Jiashi, DU Chengkan, LI Hong. Factors influencing long-term recurrence in pediatric acute lymphoblastic leukemia patients with low-risk disease at initial diagnosis: a five-year follow-up analysis of 254 cases from a single center [J]. Journal of Clinical Pediatrics, 2026, 44(7): 628-635.
[12]	GUO Xuemei, XUE Yao, WANG Yongren, RONG Liucheng, FANG Yongjun, LIN Rufeng. Clinical features and prognosis of childhood acute myeloid leukemia with CBFA2T3::GLIS2 fusion [J]. Journal of Clinical Pediatrics, 2026, 44(7): 636-643.
[13]	YANG Lijun, FU Dongxia, CUI Yan, YANG Junmei, ZHANG Liming. Clinical manifestation and genetic analysis of CHARGE syndrome caused by CHD7 gene variation [J]. Journal of Clinical Pediatrics, 2026, 44(7): 644-650.
[14]	HU Yan, YANG Fan, LIANG Aimin, MAO Meng. Identification and management of faltering growth in children: insights from the 13th International Conference on Nutrition and Growth [J]. Journal of Clinical Pediatrics, 2026, 44(6): 485-488.
[15]	LIU Ziyao, WANG Congying, WANG Hongmao, ZHANG Mingming, XU Yingjie, LAI Jianming, NIU Wenquan, LI Xiaohui. Early differentiation of Kawasaki disease with joint symptoms and systemic juvenile idiopathic arthritis with Kawasaki disease-like symptoms: a single-center retrospective study [J]. Journal of Clinical Pediatrics, 2026, 44(6): 489-498.